In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas; update on initial pipeline targets expected in late 2022/early 2023
Additi
… upfront payment and equity investment ProQR is eligible to additionally receive up to approximately $ 1. 25 billion in … oligonucleotides, or EONs, designed to recruit endogenous ADAR enzymes (Adenosine Deaminases Acting on RNA) to a selected target …
… been enrolled in a Phase 1/2 clinical trial of QR-110 in adults and children with LCA 10. Interim data are expected in … the vision loss associated with Usher syndrome type 2A. ADAR A-to-I RNA editing expert Dr. Peter A. Beal was appointed to ProQR’s scientific advisory board. LEIDEN, the Netherlands, May 09, 2018 (GLOBE …
… advancements anticipated through increased knowledge of ADAR biology, selection of models for prediction of Axiomer … molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA …
… ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides … the Company’s runway and deliver on its commitment to advance RNA therapies for diseases with high unmet need. … in 2014, it has established a leading IP estate in the ADAR editing space, a first industry partnership, and with …
… effective strategies to increase RNA editing yields of ADARs using chemical modifications and oligonucleotide design. Additionally highlighted was the potential of the Axiomer … molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer ® EONs are …
… platform uses the body’s own editing machinery called ADAR to make single nucleotide edits in RNA,” said Gerard … as targets in our collaboration with Eli Lilly. With broad applicability, and a leading patent portfolio in the ADAR editing space, Axiomer ® …
… as of end of Q2 providing runway into mid-2026, plus additional potential milestones from Lilly partnership … mid-2026, we look forward to continued execution as we advance our science and pipeline programs.” Recent Progress … P-705 ). ProQR scientists showed for the first time in the ADAR RNA editing field in vivo proof of target engagement …
… for directing site-specific A-to-I editing by endogenous ADAR enzymes Presenter: Antti Aalto, Ph.D., senior … an endogenously expressed RNA editing system called ADAR, which can direct the change of an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is …